Exceptional Weight Loss
Clinical trials show 15-22% average weight loss – more than any other medication.
Heart Health Benefits
Improves cardiovascular health while managing diabetes effectively.
FDA Approved
Latest breakthrough technology approved for both diabetes and weight management.
Why Choose Tirzepatide?
Tirzepatide represents the latest breakthrough in weight management and diabetes treatment. As a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it offers unprecedented results for patients seeking effective, long-term solutions.
I lost 45 pounds in 6 months with Tirzepatide. My energy is back, my diabetes is under control, and I feel like myself again. - Sarah M.
Mechanism of Action
- GLP-1 Receptor Activation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying
- GIP Receptor Activation: Enhances insulin sensitivity and may have direct effects on fat metabolism
- Appetite Regulation: Acts on brain receptors to reduce appetite and food intake
- Gastric Motility: Slows gastric emptying, leading to increased satiety
Transformative Results
- Significant reduction in HbA1c levels
- Improved glycemic control
- Low risk of hypoglycemia
- Cardiovascular benefits
- Average weight loss of 15-22% in clinical trials
- Sustained weight reduction
- Improved body composition
- Reduction in waist circumference
In the SURMOUNT trials, patients achieved an average of 20.9% weight loss at the highest dose...
Dosing and Administration
Route: Subcutaneous injection once weekly
Starting Dose: 2.5 mg once weekly for 4 weeks
Maintenance Doses:
- 5 mg once weekly (minimum effective dose)
- 7.5 mg once weekly
- 10 mg once weekly
- 12.5 mg once weekly
- 15 mg once weekly (maximum dose)
Injection Sites: Thigh, abdomen, or upper arm. Rotate injection sites weekly.
Side Effects
Common (≥5%):
- Nausea (12-18%)
- Diarrhea (12-16%)
- Vomiting (6-12%)
- Constipation (6-7%)
- Abdominal pain (6-9%)
- Injection site reactions
Serious (Rare):
- Pancreatitis
- Gallbladder disease
- Kidney problems
- Severe hypoglycemia (with insulin/sulfonylureas)
- Thyroid C-cell tumors (theoretical risk)
Contraindications and Precautions
Contraindications:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Known hypersensitivity to tirzepatide
Use with Caution:
- History of pancreatitis
- Severe renal impairment
- Diabetic retinopathy
- Pregnancy and breastfeeding
Telehealth Consultation Form
